


PHARMACEUTICAL 2023

ABMC AMERICAN BIO MEDICA C O R P O R A T I O N

AMERICAN BIO MEDICA CORP Rank 397 of 446





PHARMACEUTICAL 2023





The relative strengths and weaknesses of AMERICAN BIO MEDICA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMERICAN BIO MEDICA CORP compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 43% points. The greatest weakness of AMERICAN BIO MEDICA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -226%, being 270% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	769
Cost of Goods Sold	1,106
Intangible Assets	0
Liabilities, Current	3,602
Liabilities, Non-Current	6.0
Other Assets	34
Other Compr. Net Income	0
Other Expenses	139
Other Liabilities	0
Other Net Income	-166
Other Revenues	913
Property and Equipment	466
Research and Development	85
Selling, General and Administrative Expense	917

Output Variable	Value in 1000 USD
Assets	1,269
Liabilities	3,608
Expenses	2,247
Revenues	913
Stockholders Equity	-2,339
Net Income	-1,500
Comprehensive Net Income	-1,500
Economic Capital Ratio	-226%

